M&A / Deals Eli Lilly maintains M&A streak with $202m Engage Bio buyout Pharmaceutical TechnologyEli Lilly's takeover of Engage Bio marks the seventh acquisition for the big pharma since the start of 2026.Read full story pharminent May 21, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology Eli Lilly’s takeover of Engage Bio marks the seventh acquisition for the big pharma since the start of 2026. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FUJIFILM opens new iPSC facility in Madison, USNext: BioMarin bounces back as Voxzogo performs ‘bigger than expected’ in new indication Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
